Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Return on Capital Employed of 25.04% for Q2 2026, up 12408.0% year-over-year from N/an in Q2 2025, and up 59.28% quarter-over-quarter from 61.49% in Q1 2026.
Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Return on Capital Employed for 8 consecutive years, with 25.04% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 12408.0% year-over-year to 25.04%; the TTM figure through Jun 2026 stood at 25.04% (up 12408.0% YoY), while the FY2025 annual figure was 85.7%, up 371.0% from the prior year.
- Return on Capital Employed advanced to 25.04% in Q2 2026 per PHAT's latest filing, from 61.49% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 25.04% in Q2 2026 and bottomed at 149.12% in Q2 2025.
- Historically, Return on Capital Employed has averaged 92.29% across 5 years, with a median of 90.8% in 2022.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 6223 bps — and 2026, when it surged 12408 bps.
- Phathom Pharmaceuticals' Return on Capital Employed stood at 109.74% in 2022, then surged by 47 bps to 58.37% in 2023, then tumbled by 60 bps to 93.44% in 2024, then tumbled by 46 bps to 135.96% in 2025, then jumped by 82 bps to 25.04% in 2026.
- Business Quant data shows PHAT's Return on Capital Employed at 25.04% in Q2 2026, 61.49% in Q1 2026, and 135.96% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -25.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.04% |
| Mar 31, 2026 | -61.49% |
| Dec 31, 2025 | -135.96% |
| Sep 30, 2025 | -140.32% |
| Jun 30, 2025 | -149.12% |
| Mar 31, 2025 | -109.21% |
| Dec 31, 2024 | -93.44% |
| Sep 30, 2024 | -100.00% |
| Jun 30, 2024 | -86.89% |
| Mar 31, 2024 | -60.63% |
| Dec 31, 2023 | -58.37% |
| Sep 30, 2023 | -63.46% |
| Jun 30, 2023 | -82.50% |
| Mar 31, 2023 | -117.61% |
| Dec 31, 2022 | -109.74% |
| Sep 30, 2022 | -85.93% |
| Jun 30, 2022 | -93.29% |
| Mar 31, 2022 | -88.32% |
| Dec 31, 2021 | -71.10% |
| Sep 30, 2021 | -79.77% |